Oral GLP-1 is here. Here's what early data show about who…

Following FDA approval of the Wegovy tablet in December 2025, Truveta — a health data analytics company using real-world electronic health record data — analyzed early prescriptions. Their finding: 36.1% of patients who received oral semaglutide were new to GLP-1 therapy, meaning they had not previously used an injectable or any other GLP-1 drug.

This suggests the pill is expanding access to patients who had not started injectables rather than simply replacing them for existing users. Possible reasons include needle aversion, convenience preferences, or an easier entry into therapy for patients who were hesitant to begin with injections.

It is still early data. Whether this pattern holds as prescriptions scale, and whether outcomes differ between new users and switchers, will take more time to establish.

Oral semaglutide (Wegovy tablet, 25 mg once daily). This is a peptide-based GLP-1 receptor agonist — the same active molecule as injectable Wegovy, formulated as a tablet. Because semaglutide is a peptide that breaks down in the stomach, the tablet requires specific absorption conditions: patients must take it on an empty stomach first thing in the morning, with no more than 120 mL (about 4 oz) of plain water, and wait at least 30 minutes before eating, drinking anything else, or taking other medications. These requirements are built into the FDA-approved label and are clinically important for effectiveness.

FDA approved the Wegovy tablet in December 2025 for chronic weight management in adults with obesity or overweight with a weight-related condition. In clinical trials, mean weight loss at the highest dose was approximately 15–17%.

Orforglipron (Foundayo, once daily). Foundayo is a non-peptide, small-molecule GLP-1 receptor agonist — mechanistically different. Because it is not a peptide, it does not have the same stomach acid degradation issue, and can be taken without food, water, or timing restrictions. FDA approved Foundayo on April 1, 2026. Phase 3 trial data showed approximately 9.6–11.2% body weight loss at 72 weeks. With commercial insurance coverage, starting costs have been reported at approximately $25 per month.

Oral and injectable GLP-1 medications have been tested in separate clinical trials, not in direct head-to-head comparisons. Indirect comparisons from separate studies suggest:

• Semaglutide injection 2.4 mg (Wegovy, STEP trials): approximately 15–17% average weight loss
• Tirzepatide injection 15 mg (Zepbound, SURMOUNT trials): approximately 20–22% average weight loss
• Oral semaglutide 25 mg (Wegovy tablet, OW OASIS trials): approximately 15–17% average weight loss at highest dose
• Orforglipron (Phase 3): approximately 9.6–11.2% average weight loss

These comparisons are from different studies, different patient populations, and different design parameters. They should not be treated as definitive head-to-head rankings. Individual patient response to any GLP-1 medication varies significantly.

It is too early to know whether real-world outcomes for oral GLP-1 users will match trial results, and whether the administration requirements for oral semaglutide affect adherence in practice. Foundayo's real-world outcomes data are limited given its April 2026 approval.

Triple-agonist medications (like the investigational retatrutide) and new injectable options in late-stage development may change the comparative landscape further. The oral vs. injectable question will continue to evolve as more data accumulates.

• Am I a candidate for an oral GLP-1 based on my clinical history and BMI?
• Can I reliably follow the fasting and timing requirements for the Wegovy tablet, or does Foundayo's flexibility make more sense for my routine?
• How does the weight loss evidence for oral options compare to what I have experienced or might expect from an injectable?
• What would switching from an injectable to an oral mean for my treatment trajectory?
• What is the cost difference for my specific coverage situation, and which is covered?

• Weight trajectory in the first 12–16 weeks on an oral GLP-1 — a useful window for assessing early response
• Nausea, vomiting, and GI symptoms, which are common with GLP-1 therapy
• Whether the administration requirements for Wegovy tablet are consistently manageable in your daily routine
• Your prescriber's next assessment milestone

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Truveta: Early uptake of Wegovy pill — real-world data. truveta.com/blog/research/featured-research/oral-semaglutide-for-obesity-wegovy-pill/
• AJMC: FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss. ajmc.com
• FDA label for Wegovy tablet (oral semaglutide). accessdata.fda.gov (label 215256s033lbl.pdf)
• Eli Lilly: FDA approves Foundayo (orforglipron), April 2026. investor.lilly.com
• MedPage Today / Kristen Monaco: FDA approves orforglipron, April 2026. medpagetoday.com